Ethacrynic acid inhibits multiple steps in the NF-κB signaling pathway

被引:24
作者
Han, YS
Englert, JA
Delude, RL
Fink, MP
机构
[1] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15261 USA
[2] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA
[3] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15261 USA
来源
SHOCK | 2005年 / 23卷 / 01期
关键词
p65; p50; inflammation; lipopolysaccharide; pharmacology;
D O I
10.1097/01.shk.0000150629.53699.3f
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Ethacrynic acid has been used as a safe and effective diuretic for more than 30 years. In this study, we tested the hypothesis that ethacrynic acid is also an anti-inflammatory agent that inhibits signaling by the proinflammatory transcription factor NF-kappaB. We showed that ethacrynic acid inhibited luciferase expression in lipopolysaccharide-stimulated macrophage-like RAW 264.7 cells transfected with an NF-kappaB-dependent luciferase reporter vector and also inhibited NF-kappaB DNA binding in lipopolysaccharide-stimulated RAW 264.7 cells (electrophoretic mobility shift assay). Ethacrynic acid inhibited degradation of IkappaBalpha and IkappaBbeta in lipopolysaccharide-stimulated RAW 264.7 cells. Ethacrynic acid impaired DNA binding of wild-type p65 subunits of NF-kappaB in cells. However, DNA binding of a Cys(38) --> Ser p65 mutant was not inhibited by ethacrynic acid, suggesting that ethacrynic acid inhibits DNA binding by alkylating p65 at Cys(38). In a cell-free system, binding of p50 homodimers to an NF-kappaB consensus sequence was inhibited by ethacrynic acid at concentrations from 10 to 100 muM, indicating that ethacrynic acid probably also covalently modifies the p50 subunit. These data indicate that ethacrynic acid inhibits activation of the NF-kappaB pathway at multiple points and suggest that this well-studied drug warrants further investigation as a potential therapeutic for various conditions that are associated with excessive inflammation.
引用
收藏
页码:45 / 53
页数:9
相关论文
共 51 条
[1]   Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine [J].
Aizawa, S ;
Ookawa, K ;
Kudo, T ;
Asano, J ;
Hayakari, M ;
Tsuchida, S .
CANCER SCIENCE, 2003, 94 (10) :886-893
[2]  
ALKALAY I, 1995, MOL CELL BIOL, V15, P1294
[3]   ACTIVATION OF DNA-BINDING ACTIVITY IN AN APPARENTLY CYTOPLASMIC PRECURSOR OF THE NF-KAPPA-B TRANSCRIPTION FACTOR [J].
BAEUERLE, PA ;
BALTIMORE, D .
CELL, 1988, 53 (02) :211-217
[4]   I-KAPPA-B - A SPECIFIC INHIBITOR OF THE NF-KAPPA-B TRANSCRIPTION FACTOR [J].
BAEUERLE, PA ;
BALTIMORE, D .
SCIENCE, 1988, 242 (4878) :540-546
[5]   TUMOR-NECROSIS-FACTOR AND INTERLEUKIN-1 LEAD TO PHOSPHORYLATION AND LOSS OF I-KAPPA-B-ALPHA - A MECHANISM FOR NF-KAPPA-B ACTIVATION [J].
BEG, AA ;
FINCO, TS ;
NANTERMET, PV ;
BALDWIN, AS .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (06) :3301-3310
[6]   The x-ray crystal structure of the NF-κB p50•p65 heterodimer bound to the interferon β-κB site [J].
Berkowitz, B ;
Huang, DB ;
Chen-Park, FE ;
Sigler, PB ;
Ghosh, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (27) :24694-24700
[7]  
BIRKETT DJ, 1973, MOL PHARMACOL, V9, P209
[8]   Inhibition of cell proliferation and AP-1 activity by acrolein in human A549 lung adenocarcinoma cells due to thiol imbalance and covalent modifications [J].
Biswal, S ;
Acquaah-Mensah, G ;
Datta, K ;
Wu, XL ;
Kehrer, JP .
CHEMICAL RESEARCH IN TOXICOLOGY, 2002, 15 (02) :180-186
[9]   Lipid peroxidation is involved in the activation of NF-kappa B by tumor necrosis factor but not interleukin-1 in the human endothelial cell line ECV304 - Lack of involvement of H2O2 in NF-kappa B activation by either cytokine in both primary and transformed endothelial cells [J].
Bowie, AG ;
Moynagh, PN ;
ONeill, LAJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (41) :25941-25950
[10]   Inhibition of nuclear factor κB by direct modification in whole cells -: Mechanism of action of nordihydroguaiaritic acid, curcumin and thiol modifiers [J].
Brennan, P ;
O'Neill, LAJ .
BIOCHEMICAL PHARMACOLOGY, 1998, 55 (07) :965-973